Welcome to the e-CCO Library!

P724: Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, W. van de Vrie2, J. Bloemsaat-Minekus3, M. Nurmohamed4, P. Bossuyt5, A. Bodelier6, T. Rispens7, Y. van Megen3, G. D'Haens1

Created: Thursday, 21 February 2019, 9:14 AM
P724: Upadacitinib is Effective and Safe in Tofacitinib-Experienced Patients with Ulcerative Colitis: A Prospective Real-World Experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Krugliak Cleveland, N.(1)*;Friedberg, S.(1);Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Rubin, D.T.(1);
Created: Friday, 14 July 2023, 11:12 AM
P724: Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Card*1, R. Ungaro2, F. Bhayat3, A. Blake3, G. Hantsbarger3, S. Travis4

Created: Friday, 22 February 2019, 9:41 AM
P725 Trends in biologic use prior to resective surgery for inflammatory bowel disease: A Canadian population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Chopra1, E. Kennedy2, A.V. Weizman1, A. Tennakoon3, L.E. Targownik1

Created: Thursday, 30 January 2020, 10:12 AM
P725: A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. McGettigan*1, C. Mc Shane2, O. Mc Carthy1, A. Keogh1, D. Kevans2, E. Slattery1

Created: Friday, 22 February 2019, 9:41 AM
P725: Ileal pouch excision: A contemporary observational cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Worley1,2*, D. Patsouras3, K. Sahnan1,3, S. Adegbola1,3, H. Mahmood3, O. Faiz1,3, S. Clark1,3

Created: Thursday, 21 February 2019, 9:14 AM
P725: Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van De Pol, N.(1)*;van der Woude, C.J.(1);Vis, M.(2);van Doorn, M.B.A.(3);Derikx, L.A.A.P.(1);Molendijk, I.(1);de Vries, A.C.(1);
Created: Friday, 14 July 2023, 11:12 AM
P725: The impact of an integrated model of care for patients with inflammatory bowel disease in Canada
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peña-Sánchez J.N.*1, Lix L.M.2, Teare G.F.3, Li W.3, Fowler S.A.4, Jones J.L.5

Created: Wednesday, 20 February 2019, 10:36 AM
P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Bokemeyer1, S. Plachta-Danielzik2, C. Sobotzki3, W. Mohl4, M. Hoffstadt5, T. Krause6, R. Atreya7, M. von der Ohe8, U. Graefe9, L. Trentmann10, M. Eisold11, A. Linde9, S. Franzenburg13, M. Moser13, P. Hartmann14, S. Schreiber15, German IBD Study Group (GISG)

Created: Thursday, 30 January 2020, 10:12 AM
P726: Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity following antibiotic therapy—results from a prospective clinical trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ollech, J.(1)*;Yanai, H.(2);Avni Biron, I.(2);Dotan, I.(2);
Created: Friday, 14 July 2023, 11:12 AM
P726: High mortality risk after first hospital admission for inflammatory bowel disease: a nationwide registry linkage study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Opstelten J.*1, Vaartjes I.2, Siersema P.3, Bots M.2, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P726: Metalloproteinase 3: A new marker for assessing loss of response to infliximab in IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Barberio1*, R. D'Incà2, M. Dalla Gasperina1, S. Facchin1, L. Digiglio1, R. Cardin1, G. Lorenzon1, A. Rigo1, G.C. Sturniolo1

Created: Thursday, 21 February 2019, 9:14 AM
P726: Trough levels of infliximab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on infliximab maintenance therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. H. Oh*1, A-R. Yoon2, S. H. Park3, J. Kim1, N. Ham1, E. M. Song1, S. W. Hwang1,2, S. H. Park1,2, D-H. Yang1, J-S. Byeon1, S-J. Myung1, S-K. Yang1,2, B. D. Ye1,2

Created: Friday, 22 February 2019, 9:41 AM
P727 Small bowel capsule endoscopy impact on therapeutic decisions in established Crohn’s disease: Analysis of a real-world data
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E.J. Gómez, R.A. Gonzalez, L. Pereyra, J.M. Mella, G.N. Panigadi, C. Fischer, M. Roel, D.G. Cimmino, S. Pedreira, L.A. Boerr

Created: Thursday, 30 January 2020, 10:12 AM
P727: Change in Crohn's disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Halfvarson J.2, Kupcinskas L.3, Hernandez V.4, Kaimakliotis I.5, Valpiani D.6, Pedersen N.7, Duricova D.8, Kievit L.9, Dahlerup J.F.10, Fumery M.11, Salupere R.12, Arebi N.13, Nielsen K.R.14, Giannotta M.15, Oksanen P.16, Katsanos K.H.17, Vegh Z.18, Ellul P.19, Schwartz D.20, Čuković-Čavka S.21, D'Incà R.22, Turcan S.23, Magro F.24,25,26, Goldis A.27, Langholz E.28, Lakatos P.L.18, Munkholm P.1 EpiCom Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P727: Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macaluso, F.S.(1)*;Ventimiglia, M.(2);Orlando, A.(3);
Created: Friday, 14 July 2023, 11:12 AM
P727: Efficacy of vedolizumab (VDZ) by disease localisation in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Allez1*, F. Braegger2, C. Kempf2, P. Michetti3

Created: Thursday, 21 February 2019, 9:14 AM
P727: Quality of life and disease activity in children and adolescents with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Aloi*1, E. Carloni1, F. Palmacci1, M. Distante1, G. Catassi1, G. D'Arcangelo1, S. Cucchiara1, AMICI Italian IBD Association1

Created: Friday, 22 February 2019, 9:41 AM
P728 Comparative assessment of faecal microbiota transplantation and current therapies as induction treatment for active refractory ulcerative colitis: A systematic review and network meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Malandris1, P. Paschos1, A. Koukoufiki1, A. Katsoula1, A. Manolopoulos1, A. Tsapas1,2, E. Bekiari1

Created: Thursday, 30 January 2020, 10:12 AM
P728: Changes in the use of biologics in the treatment of IBD patients over time. Results from a comprehensive Norwegian registry study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Svatun Lirhus S.*1, Melberg H.O.1,2, Lie Høivik M.3, Moum B.3

Created: Wednesday, 20 February 2019, 10:36 AM